Video Reference list:
- Buglioni A, Burnett JC. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta. 2015;443:3-8. doi:10.1016/j.cca.2014.10.027. Return to content
- Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122(3):216-238. doi:10.1016/j.pharmthera.2009.02.009. Return to content
- Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883-1893. doi:10.1056/NEJMoa1915928. Return to content
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200. doi:10.1093/eurheartj/ehw128. Return to content
- Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137-e161. doi:10.1161/CIR.0000000000000509. Return to content
- Sandner P. From molecules to patients: Exploring the therapeutic role of soluble guanylate cyclase stimulators. Biol Chem. 2018;399(7):679-690. doi:10.1515/hsz-2018-0155. Return to content
- Bristow MR, Kao DP, Breathett KK, et al. Structural and functional phenotyping of the failing heart: is the left ventricular ejection fraction obsolete? J Am Coll Cardiol. 2017;5(11):772-781. doi:10.1016/j.jchf.2017.09.009. Return to content
- PubChem. Guanosine-5'-triphosphate. https://pubchem.ncbi.nlm.nih.gov/compound/135398633. Updated January 18, 2020. Accessed November 2022. PubChem. Guanosine-5'-triphosphate. https://pubchem.ncbi.nlm.nih.gov/compound/135398633. Updated January 18, 2020. Accessed November 2022. Return to content
- RCSB Protein Data Bank. 6JT0: Structure of human soluble guanylate cyclase in the unliganded state. http://www.rcsb.org/3d-view/6JT0. Updated November 6, 2019. Accessed November 2022. RCSB Protein Data Bank. 6JT0: Structure of human soluble guanylate cyclase in the unliganded state. http://www.rcsb.org/3d-view/6JT0. Updated November 6, 2019. Accessed November 2022. Return to content
- PubChem. Cyclic guanosine monophosphate. https://pubchem.ncbi.nlm.nih.gov/compound/135398570. Updated January 18, 2020. Accessed November 2022. PubChem. Cyclic guanosine monophosphate. https://pubchem.ncbi.nlm.nih.gov/compound/135398570. Updated January 18, 2020. Accessed November 2022. Return to content
- Huelsz-Prince G, Belkin AM, VanBavel E, Bakker ENTP. Activation of extracellular transglutaminase 2 by mechanical force in the arterial wall. J Vasc Res. 2013;50(5):383-395. doi:10.1159/000354222. Return to content
- PubChem. Vericiguat. https://pubchem.ncbi.nlm.nih.gov/compound/54674461. Accessed November 2022. PubChem. Vericiguat. https://pubchem.ncbi.nlm.nih.gov/compound/54674461. Accessed November 2022. Return to content
- RCSB Protein Data Bank. 6JT2: Structure of human soluble guanylate cyclase in the NO activated state. http://www.rcsb.org/3d-view/6JT2. Updated October 23, 2019. Accessed November 2022. RCSB Protein Data Bank. 6JT2: Structure of human soluble guanylate cyclase in the NO activated state. http://www.rcsb.org/3d-view/6JT2. Updated October 23, 2019. Accessed November 2022. Return to content
- Armstrong PW, Roessig L, Patel MJ, et al. A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: The VICTORIA trial. JACC Heart Fail. 2018;6(2):96-104. doi:10.1016/j.jchf.2017.08.013. Return to content
How Does Verquvo Work more information Slide 2 References:
- Gheorghiade M et al. Heart Fail Rev. 2013;18:123 Gheorghiade M et al. Heart Fail Rev. 2013;18:123 Return to content
- Boerrigter G et al. Handb Exp Pharmacol. 2009:485 Boerrigter G et al. Handb Exp Pharmacol. 2009:485 Return to content
- Breitenstein S et al. Handb Exp Pharmacol. 2017;243:225-247 Breitenstein S et al. Handb Exp Pharmacol. 2017;243:225-247 Return to content
- Armstrong PW et al. JACC Heart Fail. 2018;6:96 Armstrong PW et al. JACC Heart Fail. 2018;6:96 Return to content
- Tsai E et al. Pharmacol Ther. 2009;122:216 Tsai E et al. Pharmacol Ther. 2009;122:216 Return to content
- Sandner P. Biol Chem. 2018;399:679 Sandner P. Biol Chem. 2018;399:679 Return to content
- Kim JY et al. Sci Rep. 2016;6:36979 Kim JY et al. Sci Rep. 2016;6:36979 Return to content
- Cerra M, Pellegrino D. Curr Med Chem. 2007;14:585 Cerra M, Pellegrino D. Curr Med Chem. 2007;14:585 Return to content
How Does Verquvo Work further information Slide 3 References:
- Breitenstein S et al. Handb Exp Pharmacol. 2017;243:225-247 Breitenstein S et al. Handb Exp Pharmacol. 2017;243:225-247 Return to content
- Stasch JP and Hobbs AJ. Handb Exp Pharmacol. 2009;191:277 Stasch JP and Hobbs AJ. Handb Exp Pharmacol. 2009;191:277 Return to content
- Follmann M et al. Angew Chem Int Ed Engl. 2013;52:9442 Follmann M et al. Angew Chem Int Ed Engl. 2013;52:9442 Return to content
- Sandner P. Biol Chem. 2018;399:679 Sandner P. Biol Chem. 2018;399:679 Return to content
- Greene S et al. J Am Heart Assoc. 2013;2:e000536 Greene S et al. J Am Heart Assoc. 2013;2:e000536 Return to content
- Buys ES et al. Nitric Oxide. 2018;78:72 Buys ES et al. Nitric Oxide. 2018;78:72 Return to content
- Friebe A et al. Naunyn Schmiedebergs Arch Pharmacol. 2020;393:287 Friebe A et al. Naunyn Schmiedebergs Arch Pharmacol. 2020;393:287 Return to content
- Yandrapalli S et al. Ther Adv Cardiovasc Dis. 2018;12:217 Yandrapalli S et al. Ther Adv Cardiovasc Dis. 2018;12:217 Return to content
- Cerra M, Pellegrino D. Curr Med Chem. 2007;14:585 Cerra M, Pellegrino D. Curr Med Chem. 2007;14:585 Return to content
- Sacubitril/valsartan UK Summary of product characteristics (SmPC) https://www.medicines.org.uk/emc/product/5074/smpc Last accessed November 2022 Sacubitril/valsartan UK Summary of product characteristics (SmPC) https://www.medicines.org.uk/emc/product/5074/smpc Last accessed November 2022 Return to content
How Does Verquvo Work further information Slide 5 References:
- Boettcher M et al. Eur J Clin Pharmacol. 2021; 77(4): 527-537 Boettcher M et al. Eur J Clin Pharmacol. 2021; 77(4): 527-537 Return to content
- Verquvo US Prescribing Information Verquvo US Prescribing Information Return to content
- Boettcher M et al. Clin Pharmacokinet. 2021; 60(3): 337-351 Boettcher M et al. Clin Pharmacokinet. 2021; 60(3): 337-351 Return to content
How Does Verquvo Work further information Slide 6 References:
- Boettcher M et al. Clin Pharmacokinet. 2021; 60(3): 337-351 Boettcher M et al. Clin Pharmacokinet. 2021; 60(3): 337-351 Return to content
- Abstract 19938: VEriciguat NItroglycerin Clinical IntEraction (VENICE): A Phase 1, Multicenter, Randomized, Placebo-controlled, Double-blind Group-comparison Study in Patients With Stable Coronary Artery Disease to Evaluate Tolerability and Blood Pressure Effects of Nitroglycerin After Pre-treatment With Multiple Oral Doses of Vericiguat Abstract 19938: VEriciguat NItroglycerin Clinical IntEraction (VENICE): A Phase 1, Multicenter, Randomized, Placebo-controlled, Double-blind Group-comparison Study in Patients With Stable Coronary Artery Disease to Evaluate Tolerability and Blood Pressure Effects of Nitroglycerin After Pre-treatment With Multiple Oral Doses of Vericiguat Return to content
- Boettcher ESC-HF 2019. Abstract #1184. Boettcher ESC-HF 2019. Abstract #1184. Return to content
- Boettcher M et al. Clin Pharmacokinet. 2020; 59(11): 1407-1418 Boettcher M et al. Clin Pharmacokinet. 2020; 59(11): 1407-1418 Return to content
How Does Verquvo Work further information Slide 7 References:
- Gheorghiade M et al. Heart Fail Rev. 2013;18:123 Gheorghiade M et al. Heart Fail Rev. 2013;18:123 Return to content
- Boerrigter G et al. Handb Exp Pharmacol. 2009;191:485 Boerrigter G et al. Handb Exp Pharmacol. 2009;191:485 Return to content
- Breitenstein S et al. Handb Exp Pharmacol. 2017;243:225-247 Breitenstein S et al. Handb Exp Pharmacol. 2017;243:225-247 Return to content
- Armstrong PW et al. JACC Heart Fail. 2018;6:96-104 Armstrong PW et al. JACC Heart Fail. 2018;6:96-104 Return to content
- Follmann M et al. J Med Chem 2017;60:5146; Follmann M et al. J Med Chem 2017;60:5146; Return to content
- Mathar I et al. Circulation. 2018;138:A15553. Mathar I et al. Circulation. 2018;138:A15553. Return to content
How Does Verquvo Work further information Slide 8 References:
- Breitenstein S et al. Handb Exp Pharmacol. 2017;243:225-247 Breitenstein S et al. Handb Exp Pharmacol. 2017;243:225-247 Return to content
- Münzel T et al. Circulation. 2011;123(19):2132-2144. Münzel T et al. Circulation. 2011;123(19):2132-2144. Return to content
- Münzel T et al. Vascul Pharmacol. 2014;63(3):105-113 Münzel T et al. Vascul Pharmacol. 2014;63(3):105-113 Return to content
- Michalak M et al. Circ Heart Fail. 2018;11(3):e004813 Michalak M et al. Circ Heart Fail. 2018;11(3):e004813 Return to content
- Franssen C et al. Heart. 2016;102:320-330 Franssen C et al. Heart. 2016;102:320-330 Return to content
How Does Verquvo Work further information Slide 9 References:
- Gheorghiade M et al. Heart Fail Rev. 2013;18:123 Gheorghiade M et al. Heart Fail Rev. 2013;18:123 Return to content
- Boerrigter G et al. Handb Exp Pharmacol. 2009;191:485 Boerrigter G et al. Handb Exp Pharmacol. 2009;191:485 Return to content
- Breitenstein S et al. Handb Exp Pharmacol. 2017;243:225-247 Breitenstein S et al. Handb Exp Pharmacol. 2017;243:225-247 Return to content
- Armstrong PW et al. JACC Heart Fail. 2018;6:96-104 Armstrong PW et al. JACC Heart Fail. 2018;6:96-104 Return to content
- Follmann M et al. J Med Chem 2017;60:5146 Follmann M et al. J Med Chem 2017;60:5146 Return to content
- Mathar I et al. Circulation. 2018;138:A15553. Mathar I et al. Circulation. 2018;138:A15553. Return to content
PP-VER-GB-0027 | November 2022
Reporting adverse events and quality complaints
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 0118 206 3500 or Email: pvuk@bayer.com
Further information is available on the "contact" tab at www.bayer.co.uk.
© 2023 Bayer plc
This website contains information on Verquvo® (vericiguat) which is based on the Summary of Product Characteristics (SmPC). Intended for UK audience only.
- PP-VER-GB-0028 November 2022
